Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma.

Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma.

Item
http://www.wikidata.org/entity/Q34647911
Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-upChallenges of advanced hepatocellular carcinomaHepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapiesSkeletal muscle depletion predicts the prognosis of patients with hepatocellular carcinoma treated with sorafenibEarly Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma.Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma.Molecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities.Follow-up of multicentric HCC according to the mRECIST criteria: role of 320-Row CT with semi-automatic 3D analysis software for evaluating the response to systemic therapyNon-coding RNAs, the Trojan horse in two-way communication between tumor and stroma in colorectal and hepatocellular carcinoma.mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies.Decrease in tumor enhancement on contrast-enhanced CT is associated with improved survival in patients with hepatocellular carcinoma treated with Sorafenib.Biomarkers and Personalized Sorafenib Therapy.Prognostic value of perfusion CT in hepatocellular carcinoma treatment with sorafenib: comparison with mRECIST in longitudinal follow-up.Proposal of Japan Red Cross score for sorafenib therapy in hepatocellular carcinoma.
P2860

Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma.

Item
http://www.wikidata.org/entity/Q34647911
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Comparison of systems for asse ...... for hepatocellular carcinoma.
@ast
Comparison of systems for asse ...... for hepatocellular carcinoma.
@en
Comparison of systems for asse ...... for hepatocellular carcinoma.
@nl
type
label
Comparison of systems for asse ...... for hepatocellular carcinoma.
@ast
Comparison of systems for asse ...... for hepatocellular carcinoma.
@en
Comparison of systems for asse ...... for hepatocellular carcinoma.
@nl
prefLabel
Comparison of systems for asse ...... for hepatocellular carcinoma.
@ast
Comparison of systems for asse ...... for hepatocellular carcinoma.
@en
Comparison of systems for asse ...... for hepatocellular carcinoma.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P932
P356
P1433
P1476
Comparison of systems for asse ...... for hepatocellular carcinoma.
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P932